Max Planck Unit for the Science of Pathogens

Max Planck Unit for the Science of Pathogens
Name	Max Planck Unit for the Science of Pathogens
Established	2018
Type	Research unit
Parent organization	Max Planck Society
Director	Emmanuelle Charpentier
City	Berlin
Country	Germany

Max Planck Unit for the Science of Pathogens is a premier research institution dedicated to fundamental research on the biology of bacterial pathogens and the mechanisms of infection. Established within the framework of the Max Planck Society, the unit operates in close association with the Max Planck Institute for Infection Biology in Berlin. Its mission is to elucidate molecular processes that govern pathogenicity, with a strong emphasis on employing and developing cutting-edge technologies in genetics, biochemistry, and structural biology.

History and establishment

The unit was founded in 2018 following a strategic initiative by the Max Planck Society to concentrate and expand expertise in the field of infection biology. Its creation was significantly influenced by the groundbreaking work of its founding director, Emmanuelle Charpentier, whose co-discovery of the CRISPR-Cas9 gene-editing system revolutionized molecular biology. The establishment was formalized through a partnership between the Max Planck Society and Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, ensuring a strong bridge between basic research and clinical application. This initiative aligned with broader German and European scientific strategies, such as those promoted by the German Research Foundation and the European Research Council, to address global health challenges posed by infectious diseases.

Research focus and scientific approach

The unit's research is centered on understanding the molecular interplay between bacterial pathogens and their human hosts. A primary focus is on major human pathogens like Streptococcus pyogenes and Listeria monocytogenes, investigating their virulence mechanisms, regulatory networks, and interactions with the host immune system. The scientific approach is deeply interdisciplinary, integrating techniques from functional genomics, RNA biology, and cryo-electron microscopy. A hallmark of its methodology is the continued development and application of novel CRISPR-based tools, extending beyond genome editing to include advanced genetic screening and transcriptional regulation, to dissect complex infection processes at an unprecedented resolution.

Organizational structure and leadership

The unit is led by its founding director, Emmanuelle Charpentier, a recipient of the Nobel Prize in Chemistry and numerous other accolades including the Breakthrough Prize in Life Sciences. The research is conducted by several independent research groups, each headed by a group leader focusing on specific aspects of pathogen science, such as bacterial RNA metabolism or host-pathogen interactions. The organizational model fosters a highly collaborative and dynamic environment, with scientific direction and resource allocation overseen by the director in conjunction with the administrative framework of the Max Planck Society. The leadership maintains active advisory roles with several international bodies, including the World Health Organization.

Key research facilities and resources

The unit is housed within state-of-the-art facilities in the Berlin Institute for Medical Systems Biology building, providing direct access to shared core resources. These include advanced platforms for next-generation sequencing, high-throughput screening, and bioinformatics analysis. A central resource is a modern BSL-2 laboratory suite designed for safe work with pathogenic microorganisms. Researchers have privileged access to the nearby cryo-EM facilities at the Max Delbrück Center for Molecular Medicine and benefit from the high-performance computing infrastructure supported by the North-German Supercomputing Alliance. The unit's location in the Berlin-Buch campus creates a dense network with neighboring institutes like the Leibniz-Forschungsinstitut für Molekulare Pharmakologie.

Notable scientific contributions and discoveries

Under the leadership of Emmanuelle Charpentier, the unit has produced significant insights into the function of the CRISPR-Cas9 system and its repurposing for precise genome engineering. Subsequent research has unveiled novel aspects of bacterial immune systems and their application in biotechnology. The unit's teams have published landmark studies in journals such as *Nature* and *Science* detailing the regulatory RNA pathways in Streptococcus pyogenes that control virulence factor expression. Other key discoveries include the identification of new bacterial secretion system components and host cell factors critical for the intracellular lifecycle of Listeria monocytogenes, providing potential targets for novel antimicrobial strategies.

Collaborations and partnerships

The unit maintains an extensive network of national and international collaborations, fundamental to its translational goals. Its primary institutional partnership is with Charité – Universitätsmedizin Berlin, facilitating access to clinical isolates and patient-derived models. It is a key node in several multinational consortia funded by the European Commission, such as those addressing antimicrobial resistance. The unit also collaborates closely with other Max Planck Institutes, including the Max Planck Institute of Biochemistry and the Max Planck Institute for Molecular Genetics. Further partnerships extend to pharmaceutical industry leaders and global health organizations, ensuring its basic research informs the development of new diagnostics and therapeutics.

Category:Max Planck Society Category:Research institutes in Berlin Category:Medical and health organizations based in Germany Category:Infection-related organizations